BidaskClub lowered shares of Cascadian Therapeutics (NASDAQ:CASC) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday, March 7th.
A number of other research analysts also recently commented on CASC. Zacks Investment Research raised shares of Cascadian Therapeutics from a hold rating to a buy rating and set a $4.50 target price on the stock in a research report on Monday, November 13th. Raymond James Financial downgraded shares of Cascadian Therapeutics from an outperform rating to a market perform rating in a research report on Wednesday, January 31st. Finally, ValuEngine raised shares of Cascadian Therapeutics from a strong sell rating to a sell rating in a research report on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $6.17.
Cascadian Therapeutics (CASC) traded down $0.04 during midday trading on Wednesday, reaching $9.98. 2,000 shares of the company’s stock were exchanged, compared to its average volume of 1,092,996. The stock has a market cap of $506.61, a P/E ratio of -7.48 and a beta of 3.79. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $10.21.
Several large investors have recently added to or reduced their stakes in CASC. Schwab Charles Investment Management Inc. bought a new stake in shares of Cascadian Therapeutics in the 2nd quarter valued at about $225,000. Teachers Advisors LLC bought a new stake in shares of Cascadian Therapeutics in the 2nd quarter valued at about $252,000. TIAA CREF Investment Management LLC bought a new stake in shares of Cascadian Therapeutics in the 2nd quarter valued at about $347,000. New York State Common Retirement Fund bought a new stake in shares of Cascadian Therapeutics in the 2nd quarter valued at about $136,000. Finally, Northern Trust Corp boosted its holdings in shares of Cascadian Therapeutics by 415.5% in the 2nd quarter. Northern Trust Corp now owns 382,469 shares of the biopharmaceutical company’s stock valued at $1,420,000 after buying an additional 308,270 shares in the last quarter. Institutional investors and hedge funds own 81.38% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://ledgergazette.com/2018/03/14/cascadian-therapeutics-casc-cut-to-buy-at-bidaskclub.html.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.